SpringWorks Therapeutics Q2 EPS $(1.25) Beats $(1.26) Estimate; Cash, Cash Equivalents And Marketable Securities Of $476.7M
Portfolio Pulse from Benzinga Newsdesk
SpringWorks Therapeutics (NASDAQ:SWTX) reported Q2 losses of $(1.25) per share, beating the analyst consensus estimate of $(1.26) by 0.79 percent. This is an 11.35 percent increase over losses from the same period last year. The company also reported cash, cash equivalents and marketable securities of $476.7M.
August 04, 2023 | 10:52 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
SpringWorks Therapeutics reported better than expected Q2 losses and has a strong cash position. This could positively impact the stock in the short term.
SpringWorks Therapeutics reported a smaller loss than expected, which is generally seen as positive by the market. Additionally, the company's strong cash position indicates financial stability, which could also be viewed positively by investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100